1. Participating in the TICO trial and received a selected blinded investigational agent or placebo for that agent at selected sites. NOTE: A list of selected investigational agents will be posted on the INSIGHT website. 2. Willingness to strictly adhere to the randomly allocated dosage number and schedule for vaccine administration 3. Participant is between Day 28 and Day 90 TICO visits inclusive at the time of randomization 4. At the time of screening for this protocol, experienced sustained recovery (i.e. the primary endpoint in TICO) for at least two consecutive weeks, i.e. having returned uninterrupted to the person’s premorbid living facility (or equivalent) for at least 2 consecutive weeks 5. Ability and willingness of participant (or legally authorized representative [LAR]) to provide informed consent prior to initiation of any study procedures

1. Participating in the TICO trial and received a selected blinded investigational agent or placebo for that agent at selected sites. NOTE: A list of selected investigational agents will be posted on the INSIGHT website. 2. Willingness to strictly adhere to the randomly allocated dosage number and schedule for vaccine administration 3. Participant is between Day 28 and Day 90 TICO visits inclusive at the time of randomization 4. At the time of screening for this protocol, experienced sustained recovery (i.e. the primary endpoint in TICO) for at least two consecutive weeks, i.e. having returned uninterrupted to the person’s premorbid living facility (or equivalent) for at least 2 consecutive weeks 5. Ability and willingness of participant (or legally authorized representative [LAR]) to provide informed consent prior to initiation of any study procedures